Paradigm Biopharmaceuticals (ASX:PAR) Receipts from Customers : A$0.03 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Receipts from Customers?

Paradigm Biopharmaceuticals's Receipts from Customers for the six months ended in Dec. 2023 was A$0.03 Mil.

Paradigm Biopharmaceuticals's Receipts from Customers for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.03 Mil.

Paradigm Biopharmaceuticals Receipts from Customers Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Receipts from Customers can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Receipts from Customers Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Receipts from Customers

Get a 7-Day Free Trial

0.08

0.02

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Receipts from Customers	Get a 7-Day Free Trial												0.06	0.03	0.02	-	0.03

Paradigm Biopharmaceuticals Receipts from Customers Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Receipts from Customers represents payment received from customers in the direct cash flow method.

Receipts from Customers for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.03 Mil.

Paradigm Biopharmaceuticals Receipts from Customers Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Receipts from Customers provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Receipts from Customers

Comparable Companies

Traded in Other Exchanges

PBIGF:USA

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).